LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Listă Acțiuni・Incyte Corp

Incyte Corp

Închisă

SectorSănătate

97.31 0.18

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

94.55

Maxim

97.83

Indicatori cheie
By Trading Economics
Venit	4.1M 303M
Vânzări	-234M 1.3B
P/E Medie Sector	13.445 49.701
EPS	1.81
Marjă de profit	23.834
Angajați	2,844
EBITDA	-47M 367M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+12.15% upside

Dividende
By Dow Jones
Următoarele câștiguri	28 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-31M 19B
Deschiderea anterioară	97.13
Închiderea anterioară	97.31

Sentimentul știrilor

By Acuity

37%

63%

95 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

59.52 / 62.66 Suport & Rezistență

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 mai 2026, 22:48 UTC

Achiziții, Fuziuni, Preluări

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mai 2026, 16:49 UTC

Câștiguri

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mai 2026, 16:26 UTC

Principalele dinamici ale pieței

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mai 2026, 22:33 UTC

Achiziții, Fuziuni, Preluări

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mai 2026, 21:53 UTC

Câștiguri

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mai 2026, 21:02 UTC

Câștiguri

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mai 2026, 20:55 UTC

Câștiguri

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mai 2026, 20:30 UTC

Acțiuni populare

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mai 2026, 20:20 UTC

Câștiguri

Webull 1Q Adj EPS 3c >BULL

21 mai 2026, 20:20 UTC

Câștiguri

Webull 1Q Rev $159.9M >BULL

21 mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mai 2026, 20:18 UTC

Câștiguri

Webull 1Q Loss/Shr 4c

21 mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mai 2026, 18:58 UTC

Câștiguri

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mai 2026, 17:01 UTC

Câștiguri

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mai 2026, 16:20 UTC

Market Talk

Câștiguri

Stellantis Targets Distant but Constructive -- Market Talk

21 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

12.15% sus

Prognoză pe 12 luni

Medie 108.88 USD 12.15%

Maxim 135 USD

Minim 75 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 18 analiști care au acordat evaluări ale acțiunilor Incyte Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

95 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation